NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Announces Earnings Results

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) released its earnings results on Friday. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.01), FiscalAI reports. The business had revenue of $0.52 million during the quarter.

NovaBay Pharmaceuticals Stock Down 0.9%

Shares of NovaBay Pharmaceuticals stock traded down $0.01 on Friday, hitting $1.06. 163,616 shares of the company traded hands, compared to its average volume of 2,185,460. The company has a 50-day moving average price of $1.72 and a 200 day moving average price of $1.02. NovaBay Pharmaceuticals has a 12-month low of $0.46 and a 12-month high of $4.44. The company has a market cap of $6.37 million, a PE ratio of -0.11 and a beta of 0.62.

NovaBay Pharmaceuticals Announces Dividend

The business also recently announced a dividend, which was paid on Monday, September 29th. Shareholders of record on Wednesday, October 1st were paid a dividend of $0.80 per share. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a dividend yield of 3,791.0%.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.